Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of multiple infusions of mononuclear bone marrow cells in patients with chronic liver diseases.


Clinical Trial Description

This is a safety/efficacy phase II, open, randomized, controlled clinical trial, with two arms. The study population will consist of 30 patients with chronic decompensated liver disease (Child-Pugh B or C). The candidates included in the study will be asked to voluntarily participate and sign the written consent.

The patients will be allocated randomly into 2 groups: in group A, the patients will undergo the intervention; and in group B, the patients will be the controls. Patients of both groups will receive clinical follow-up. They will be maintained on drug therapy commonly used in patients with cirrhosis, which may include: spironolactone, furosemide, lactulose, metronidazole, neomycin, analogs of nucleoside / nucleotide in patients with hepatitis B, and vitamin complexes.

All patients included in Group A will undergo cell therapy according to the technique described as follows: on day 1 (D-1), patients will be hospitalized to undergo the bone marrow puncture through the iliac crest. 150 to 200 ml of bone marrow aspirate will be collected. The procedure will be done under local anesthesia and sedation. The fraction of mononuclear cells will be isolated from the aspirated marrow by the SEPAX (System of cell processing) - Biosafe, Switzerland.

The enriched fraction of collected mononuclear cells will be resuspended in saline. The obtained cell populations will be analyzed by flow cytometry for its characterization, and then diluted in 20 ml saline. The cells will be injected 3 times throughout the study, on days 1 (D-1), 30 (D-30) and 60 (D-60).

Patients will undergo a series of clinical and laboratory evaluations and will also be submitted to the following procedures:

- Cell blood count

- Biochemical analysis (measurement of electrolytes - sodium and potassium)

- Renal function tests (urea and creatinine)

- Liver profile tests (total proteins and fractions, bilirubin, prothrombin time, transaminases, alkaline phosphatase, gamma-GT)

- Metabolic profile (glucose, total cholesterol and fractions, triglycerides)

- Thyroid profile tests

- Serology required for blood transfusion and bone marrow transplant in Brazil

- Alpha-fetoprotein

- Beta-HCG (human chorionic gonadotropin), for women

- Handgrip dynamometer

- Treadmill test

- Six-minute walk test

- Abdomen doppler ultrasound

- Magnetic resonance imaging of the upper abdomen with elastography

- Measurement of serum factors

- Shear wave elastography

Also, the patients will respond to questions from the SF (Short Form) -36 questionnaire (for assessment of quality of life).

Clinical follow-up will be kept for patients who suspend their participation in the study for any adverse event and / or laboratory abnormality, or for the patient's own desire, following insurance protocols. In addition to the clinical and surgical follow-up, specific medical care will be offered to patients who experience adverse events, until stabilization of the patient, even if the target date for completion of the study has been exceeded. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02171949
Study type Interventional
Source Hospital Sao Rafael
Contact André C Lyra, PhD
Phone 557132816455
Email aclyra@live.com
Status Recruiting
Phase Phase 2
Start date April 2015
Completion date June 2019

See also
  Status Clinical Trial Phase
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Recruiting NCT05904470 - A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Phase 2
Completed NCT02138253 - A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV Phase 2
Recruiting NCT02652351 - Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis Phase 1
Completed NCT00794482 - Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity. Phase 3
Completed NCT00856713 - Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers Phase 1
Completed NCT02163512 - Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
Completed NCT00857480 - Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin Phase 1
Completed NCT00006164 - Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Phase 3
Completed NCT03486912 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Phase 2
Completed NCT00698464 - Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function Phase 1
Completed NCT02778425 - The Treatment of Hepatocirrhosis and Portal Hypertension N/A
Completed NCT03445208 - A Study of Experimental Medication BMS-986036 Given to Healthy Participants Phase 1
Completed NCT03420768 - A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C Phase 2
Completed NCT03804593 - HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)
Completed NCT03712280 - MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) Phase 2
Completed NCT02230670 - A Study of IDN-6556 in Subjects With Liver Cirrhosis Phase 2
Completed NCT02230683 - A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension Phase 2
Completed NCT01135628 - Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy N/A